[Essential hypertension and natriuretic peptides].
Kanmatsuse
Katsuo
K
Second Department of Internal Medicine, Nihon University School of Medicine.
Fujita
Hirotaka
H
D000375:Aging; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000235:genetics / Q000502:physiology*; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D011725:Pyridines / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000502:physiology; D012982:Sodium, Dietary; D013312:Stress, Physiological; D013841:Thiazepines / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D004791:Enzyme Inhibitors; D011725:Pyridines; D012982:Sodium, Dietary; D013841:Thiazepines; C106266:omapatrilat; D009320:Atrial Natriuretic Factor